Table 1 Summary statistics of the studied populations in the 6 selected studies

Publication year

2008

2006

2010

2010

2007

2009

Country

North and South America

USA Chicago

Japan

Japan

Korea

Japan

Active/control

Pioglitazone vs glimepiride

Pioglitazone vs glimepiride

Pioglitazone vs metformin

Pioglitazone vs standard therapy (control)

Pioglitazone vs gliclazide (control)

Pioglitazone vs group with their previous antidiabetic regimen (control)

Sample size

543 patients with type 2 diabetes and coronary disease

462 adults with type 2 diabetes

55 patients with type 2 diabetes mellitus

26 patients with stable angina and type 2 diabetes

40 patients with type 2 diabetes

54 patients with type 2 diabetes and stable angina pectoris

Age in years (mean ± SD)

60 ± 9.4 P/59.7 ± 9.1 C

58.9 ± 7.8 P/59.8 ± 8.1 C

67 ± 10 P/66 ± 10 M

67.0 ± 7.5 P/63.0 ± 10.5 C

63.1 ± 7.2 P/64.2 ± 7.1 C

68.6 ± 7.9 P/66.8 ± 8.1 C

Baseline HbA1c, % (mean ± SD)

7.4 ± 1 P/7.4 ± 1 C

7.44 (1.01) P/7.36 (0.95) G

7.9 ± 1.7 P/7.9 ± 1.3 M

6 ± 1.3 P/5.4 ± 0.9 C

9.0 ± 2.3 P/8.8 ± 2.2 C

7.17 ± 0.72 P/6.80 ± 0.85 C

Baseline fasting glucose, mg/dL (mean ± SD)

147.2 ± 41 P/148 ± 43.4 C

149.2 (48.3) P/148.2 (44.7) C

Not supplied

103 ± 12 P/99 ± 12 C

9.85 ± 1.27 P/9.51 ± 0.96 C

139.3 ± 35.3 P/129.2 ± 27.0 C

BMI (mean ± SD)

32.1 ± 5.3 P/32 ± 5.2 C

32.2 ± 5.1 P/32.0 ± 5.1 C

22.0 ± 2.3 P/24.9 ± 3.7 C

Not supplied

24.3 ± 4.1 P/24.1 ± 3 C

23.8 ± 3.0 P/24.1 ± 2.1 C

Median follow-up

18 months

72 weeks

12 months

6 months

3 months

6 months

 HbA1C post ttt (diabetics/non-diabetics) (mean ± SD)

6.9 ± 0.9 P/7 ± 1 C

Not supplied

7.1 ± 1.2 P/7.1 ± 1.1 C

5.8 ± 0.8 P/5.3 ± 0.8 C

7.1 ± 1.3 P/7.1 ± 1.2 C

6.50 ± 1.05 P/6.81 ± 0.87 C

 Fasting glucose post ttt (diabetics/non-diabetics) (mean ± SD)

139.3 ± 29.1 P/147.9 ± 33.8 C

Not supplied

Not Supplied

97 ± 14 P/102 ± 21 C

7.95 ± 1.03 P/7.47 ± 0.74 C

113.7 ± 28.9 P/137.8 ± 39.8 C